Premium
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-21 | Ms. Karen Mindy FirestoneIndependent Director | 3,80k | 51,34k | Achat | 13,51 | 66,90k | 6,02% |
| 2026-03-02 | Mr. James M. FratesCFO | -7,91k | 114,85k | Vente | 14,52 | 210,02k | -3,63% |
| 2026-03-02 | Ms. Gina M. MazzarielloChief Legal Officer & General Counsel | -6,84k | 99,38k | Vente | 14,52 | 59,04k | -10,39% |
| 2026-03-02 | Dr. Camille L. BedrosianChief Medical Officer | -6,46k | 94,21k | Vente | 14,58 | 88,81k | -6,78% |
| 2026-03-02 | Mr. Joshua B. CohenCo-Founder, Co-CEO & Director | -29,28k | 424,12k | Vente | 14,48 | 3,11M | -0,93% |
| 2026-03-02 | Mr. Justin B. KleeCo-CEO & Director | -29,28k | 423,76k | Vente | 14,47 | 3,07M | -0,95% |
| 2026-02-23 | Ms. Gina M. MazzarielloChief Legal Officer & General Counsel | -3,42k | 48,35k | Vente | 14,14 | 40,76k | -7,74% |
| 2026-02-02 | Mr. Justin B. KleeCo-CEO & Director | -15,50k | 227,62k | Vente | 14,69 | 3,10M | -0,50% |
| 2026-02-02 | Ms. Gina M. MazzarielloChief Legal Officer & General Counsel | -3,45k | 50,52k | Vente | 14,65 | 43,09k | -7,41% |
| 2026-02-02 | Mr. Joshua B. CohenCo-Founder, Co-CEO & Director | -15,50k | 227,59k | Vente | 14,68 | 3,10M | -0,50% |
| 2026-02-02 | Mr. James M. FratesCFO | -3,56k | 52,10k | Vente | 14,65 | 200,83k | -1,74% |
| 2026-01-15 | Mr. Justin B. KleeCo-CEO & Director | 61,81k | 467,92k | Derivative Exercise and Retained Stock | 7,57 | 3,08M | 2,05% |
| 2026-01-15 | Mr. Justin B. KleeCo-CEO & Director | -138,19k | 831,49k | Derivative Exercise and Sale | 7,57 - 13,89 | 3,08M | - |
| 2026-01-15 | Mr. Joshua B. CohenCo-Founder, Co-CEO & Director | 61,83k | 468,08k | Derivative Exercise and Retained Stock | 7,57 | 3,08M | 2,05% |
| 2026-01-15 | Mr. Joshua B. CohenCo-Founder, Co-CEO & Director | -138,17k | 832,17k | Derivative Exercise and Sale | 7,57 - 13,83 | 3,08M | - |
| 2026-01-12 | Dr. George Mclean MilneIndependent Chairman of the Board | -17,78k | 0,00 | Other Disposition | - | 812,88k | -2,14% |
| 2026-01-06 | Mr. Justin B. KleeCo-CEO & Director | -7,72k | 85,59k | Vente | 11,09 | 3,02M | -0,26% |
| 2026-01-06 | Mr. Joshua B. CohenCo-Founder, Co-CEO & Director | -7,72k | 85,60k | Vente | 11,09 | 3,02M | -0,26% |
| 2026-01-06 | Mr. James M. FratesCFO | -3,33k | 36,95k | Vente | 11,11 | 194,38k | -1,68% |
| 2025-12-23 | Ms. Karen Mindy FirestoneIndependent Director | 8,10k | 100,85k | Achat | 12,45 | 63,10k | 14,73% |
| 2025-12-01 | Dr. Camille L. BedrosianChief Medical Officer | -6,58k | 94,42k | Vente | 14,35 | 78,17k | -7,76% |
| 2025-09-30 | Dr. Camille L. BedrosianChief Medical Officer | -12,04k | 175,52k | Vente | 14,58 | 70,17k | -14,65% |
| 2025-09-30 | Ms. Gina M. MazzarielloChief Legal Officer & General Counsel | -8,83k | 128,67k | Vente | 14,58 | 37,37k | -19,11% |
| 2025-09-30 | Mr. Joshua B. CohenCo-Founder, Co-CEO & Director | -29,93k | 429,47k | Vente | 14,34 - 15,00 | 3,01M | -0,99% |
| 2025-09-30 | Mr. James M. FratesCFO | -10,56k | 154,65k | Vente | 14,65 | 189,79k | -5,27% |
| 2025-09-30 | Mr. Justin B. KleeCo-CEO & Director | -29,98k | 430,95k | Vente | 14,37 - 15,01 | 3,01M | -0,99% |
| 2025-08-12 | Ms. Gina M. MazzarielloChief Legal Officer & General Counsel | -30,00k | 246,15k | Automatic Disposition | 8,07 - 8,34 | 18,81k | -61,46% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
